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Pharmacokinetic parameters were summarized across studies for 
each drug using a random-effect meta-analysis approach, using 
the metafor package in R (R-project.org). The weighted mean 
parameter (q) with its standard error (SE) and the variance of the 
inter-individual variability component (w) were computed as:  
         
  
 
where M* is the summary parameter (q or w) and VM* the variance 
of the summary parameter (SE2); Yi is the parameter estimate of 
the ith study and Wi* is the  weight associated to the ith study, 
defined as the inverse of the sum of the within- and between- 
study variances.  
Concordance between individual and summary parameters was 
assessed using Forest-plots. To test robustness, difference in 
simulated curves based on published and summary parameters was 
performed using efavirenz (EFV) as a probe drug. 
References concentration vs. time curves over a dosing interval 
were simulated in 1000 patients using NONMEM® based on the 
summary population PK estimates of CL, Vz and ka with inter-
patient variability, as appropriate. 
• Many Pop-Pk studies are available for ART drugs that provide useful information regarding their kinetics, but standardization across 
studies is seldom performed.  
• Such a meta-analysis approach incorporating the results of several populations might thus provide a better description of drug 
pharmacokinetic profile. This approach will be further refined and implemented in the Bayesian TDM of ART with the integration of 
relevant influencing covariates. 
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To summarize published population pharmacokinetic (Pop-PK) estimates of antiretroviral drugs (ART) in order to derive reference 
pharmacokinetic curves that can be used for therapeutic drug monitoring (TDM) guided dosage adjustment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBJECTIVE 
METHODS 
CONCLUSION 
RESULTS: The example of Efavirenz 
• CL was in good agreement throughout all 5 Pop-PK models, suggesting 
that target concentrations can be derived with good precision. 
Absorption was however very heterogeneously described. 
• Comparison of the percentiles curves after simulation based on the 
summary model or the published study parameters did not reveal any 
major bias in EFV concentrations over the dosing interval, except in 
the few hours after drug intake (maximal bias of 20%) 
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A systematic search of Pop-PK studies of 6 ART (efavirenz, 
nevirapine, etravirine, darunavir, atazanavir, lopinavir) in adult 
patients was performed in PubMed.  
In each study, pharmacokinetic parameters were derived for a 
typical “baseline” patient (Caucasian male 70 kg, no influencing 
genetic variants, concomitant medications, nor pathophysiological 
conditions modulating drug kinetics). 
 A 1-compartment model was mostly used and retrieved 
parameters were: clearance (CL), terminal volume of distribution 
(Vz) and absorption rate constant (ka) with standard errors and 
interpatient variability. For bi-compartment models, Vz was 
derived from CL/λz. Various absorption models (first order, zero 
order, mixed absorption, with or without lag time) were reported, 
which were standardized for a first-order absorption process using 
the mean absorption time MAT=1/ka: 
 
Standard errors on estimated and derived parameters for the 
baseline typical patient were computed by applying the error 
propagation method. Standard errors on inter-patient variability 
were directly retrieved from the published papers.  
Forest plots representing mean parameter estimate with 95% CI (black dots and lines) and inter-individual variability (red lines) for the individual study and the summary parameter (n= number of concentrations) 
